Oncolys Biopharma (4588.T) traded up 6.24 % during a 24 hours period ending at 12:52 AM Central Europe on Wednesday 28th. One Oncolys Biopharma stock can currently be bought for about JPY 6,980 on popular exchanges. Current supply of Oncolys Biopharma stocks is 29.4 mn. Oncolys Biopharma has a current market capitalization of JPY 185.5 bn and approximately JPY 9.9 bn worth of Oncolys Biopharma was traded on exchanges in the last 24 hours. Since last month end, Oncolys Biopharma has traded 10.53 % up. Simple moving average of last 200 days is at JPY 3,152.52. The highest price of past 52 weeks was recorded at JPY 7,020 on 10/06/2026. 52 weeks low was at JPY 668 on 10/30/2025.

Here is how related stocks have performed in the past 24 hours:

  • Tomen Devices (2737.T) traded down -0.62 % and now trades at JPY 32,450. Tomen Devices has a market capitalisation of JPY 218.3 bn. Current price/earnings ratio for Tomen Devices is 9.4.

  • Okasan Securities (8609.T) traded down -1.11 % and now trades at JPY 1,065. Current market capitalisation for Okasan Securities is JPY 217.2 bn. Okasan Securities has a current price to earnings ratio of 7.8.

  • Hokuriku Electric Power (9505.T) traded up 1.5 % and now trades at JPY 1,085. Hokuriku Electric Power has a market capitalisation of JPY 222.2 bn. Hokuriku Electric Power has a current price to earnings ratio of 4.64.

  • Future (4722.T) traded up 0.12 % and now trades at JPY 2,428. Current market capitalisation for Future is JPY 215.4 bn. Future has a current price to earnings ratio of 17.52.

  • Starts (8850.T) traded up 1.97 % and now trades at JPY 4,580. Starts has a market capitalisation of JPY 216.2 bn. Current price/earnings ratio for Starts is 8.66.

About Oncolys Biopharma

Oncolys BioPharma Inc. is a health care biotechnology company based in Tokyo, Japan. The company specializes in conducting research, development, manufacturing, importing, and exporting oncolytic viruses, drugs, and tumor diagnostic agents. Their product pipeline includes Telomelysin (OBP-301), an oncolytic adenovirus in Phase I clinical stage for the treatment of esophageal cancer and hepatocellular carcinoma, as well as in Phase II clinical trial for the treatment of melanoma; OBP-801, a histone deacetylase inhibitor in Phase I clinical study for the treatment of solid tumors; and OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor in Phase II clinical trial for the treatment of HIV infection. Additionally, the company develops TelomeScan (OBP-401 and OBP-1101) for detecting living circulating tumor cells in blood from cancer patients. Oncolys BioPharma Inc. was founded in 2004 and is headquartered in Tokyo, Japan. Their website is www.oncolys.com , and they are listed on the Tokyo Stock Exchange. The IPO date was December 6, 2013.